IQVIA (NYSE:IQV) Price Target Raised to $325.00

Key Points

• JPMorgan raised IQVIA’s price target to $325 from $295 and maintained an “overweight” rating, implying 17.44% upside from the prior close. Other analysts have also lifted targets, while the consensus rating remains “Moderate Buy.”
• IQVIA exceeded third-quarter expectations, reporting adjusted EPS of $3.34 and revenue of $4.43 billion, up 8% year over year. Management also raised fiscal 2026 guidance and cited strong clinical bookings as a positive forward indicator.
• Shares rose 1.9% to $276.73, near the company’s 12-month high, while institutional investors own 89.62% of the stock. Insiders have sold 10,023 shares worth approximately $2.4 million over the past three months.

IQVIA (NYSE:IQV - Get Free Report) had its target price increased by equities researchers at JPMorgan Chase & Co. from $295.00 to $325.00 in a report released on Wednesday, Benzinga reports. The firm currently has an "overweight" rating on the medical research company's stock. JPMorgan Chase & Co.'s price objective would indicate a potential upside of 17.44% from the stock's previous close.

IQV has been the topic of a number of other research reports. HSBC lifted their target price on IQVIA from $280.00 to $300.00 and gave the stock a "buy" rating in a research report on Tuesday, September 1st. Jefferies Financial Group raised their price target on IQVIA from $220.00 to $290.00 and gave the stock a "buy" rating in a research note on Wednesday, July 29th. Mizuho lifted their price target on IQVIA from $275.00 to $300.00 and gave the stock an "outperform" rating in a research report on Wednesday, October 7th. Wall Street Zen upgraded IQVIA from a "hold" rating to a "buy" rating in a research note on Saturday, September 12th. Finally, BMO Capital Markets boosted their price objective on IQVIA from $270.00 to $305.00 in a research note on Monday, October 19th. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $285.35.

IQVIA Stock Up 1.9%

Shares of NYSE:IQV traded up $5.18 during trading on Wednesday, hitting $276.73. 982,081 shares of the company were exchanged, compared to its average volume of 1,691,587. The firm's 50 day moving average price is $264.74 and its 200-day moving average price is $209.94. IQVIA has a 12-month low of $154.50 and a 12-month high of $284.50. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. The stock has a market capitalization of $45.55 billion, a P/E ratio of 34.29, a PEG ratio of 2.46 and a beta of 1.17.

IQVIA (NYSE:IQV - Get Free Report) last posted its earnings results on Tuesday, October 27th. The medical research company reported $3.34 EPS for the quarter, beating analysts' consensus estimates of $3.26 by $0.08. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm had revenue of $4.43 billion for the quarter, compared to the consensus estimate of $4.37 billion. During the same period last year, the firm posted $3.00 EPS. The company's revenue was up 8.0% on a year-over-year basis. On average, research analysts predict that IQVIA will post 11.54 earnings per share for the current fiscal year.

Insider Activity

In other IQVIA news, insider James G. Berkshire sold 2,668 shares of the stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $261.33, for a total transaction of $697,228.44. Following the completion of the sale, the insider directly owned 10,890 shares of the company's stock, valued at approximately $2,845,883.70. This trade represents a 19.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Bhavik Patel sold 1,855 shares of the stock in a transaction that occurred on Friday, July 31st. The stock was sold at an average price of $235.27, for a total value of $436,425.85. Following the sale, the insider directly owned 1,348 shares of the company's stock, valued at $317,143.96. The trade was a 57.91% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 10,023 shares of company stock valued at $2,413,394. Insiders own 1.70% of the company's stock.

Institutional Investors Weigh In On IQVIA

Several large investors have recently modified their holdings of IQV. North Dakota State Investment Board grew its position in IQVIA by 0.8% in the 3rd quarter. North Dakota State Investment Board now owns 5,063 shares of the medical research company's stock valued at $1,361,000 after buying an additional 40 shares during the last quarter. Apella Capital LLC raised its position in IQVIA by 4.7% during the 3rd quarter. Apella Capital LLC now owns 1,235 shares of the medical research company's stock worth $319,000 after buying an additional 55 shares during the last quarter. Breakwater Capital Group raised its position in IQVIA by 3.2% during the 2nd quarter. Breakwater Capital Group now owns 2,073 shares of the medical research company's stock worth $401,000 after buying an additional 64 shares during the last quarter. Fortitude Family Office LLC lifted its stake in shares of IQVIA by 17.2% in the 3rd quarter. Fortitude Family Office LLC now owns 443 shares of the medical research company's stock worth $119,000 after acquiring an additional 65 shares during the period. Finally, First Growth Capital LLC lifted its stake in shares of IQVIA by 3.2% in the 1st quarter. First Growth Capital LLC now owns 2,173 shares of the medical research company's stock worth $375,000 after acquiring an additional 68 shares during the period. Hedge funds and other institutional investors own 89.62% of the company's stock.

Key Headlines Impacting IQVIA

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: Third-quarter earnings and revenue exceeded expectations. IQVIA reported adjusted EPS of $3.34, above the $3.26 consensus estimate, while revenue rose 8% year over year to approximately $4.43 billion, ahead of the $4.37 billion forecast. EPS increased from $3.00 in the year-ago quarter. IQVIA Reports Third-Quarter 2026 Results
• Positive Sentiment: Management raised its fiscal 2026 guidance. IQVIA now expects revenue of $17.35 billion to $17.50 billion and adjusted EPS of $12.90 to $13.00. The revenue range brackets the roughly $17.41 billion analyst consensus, indicating confidence that recent operating momentum will continue. IQVIA Holdings Boosts FY26 Outlook
• Positive Sentiment: Clinical demand and bookings provided encouraging forward indicators. Clinical bookings reached $11.7 billion on a trailing-12-month basis, described as the strongest level since 2022. Strong R&D Solutions performance, improved execution and robust bookings were key drivers of the quarterly beat. IQVIA Signals 2026 Outlook
• Positive Sentiment: Deutsche Bank raised its price target to $310 from $300 and maintained a Buy rating, reinforcing the view that the earnings beat and upgraded outlook could support additional upside. Deutsche Bank Adjusts IQVIA Price Target
• Neutral Sentiment: Despite the strong results, some early trading commentary indicated initial hesitation, suggesting investors may have already priced in part of the earnings improvement. The subsequent guidance increase and analyst price-target hike provided stronger support for the stock.

IQVIA Company Profile

IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.

Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.